SAM #26-005169

NIH Sole Source Procurement – Illumina MiSeq i100 System for Clinical Research

The National Institutes of Health (NIH), through its National Institute on Aging (NIA) and Department of Transfusion Medicine (DTM), has announced its intent to award a sole source contract to Illumina, Inc. for the purchase of the Illumina MiSeq i100 System, a next-generation sequencing platform. - The procurement is for one Illumina MiSeq i100 System to support clinical research and assay development for hepatitis viruses and transfusion-transmitted pathogens. - Illumina, Inc. is the original equipment manufacturer (OEM) and will provide both the instrument and associated servicing. - The system must deliver high data accuracy, low-to-moderate throughput, rapid turnaround, flexible run configurations, cost efficiency, and integrated workflows. - The contract will be a firm fixed price purchase order, justified as a sole source under FAR Part 13 Simplified Acquisition Procedures due to the unique capabilities of the Illumina system. - The period of performance is one year, from June 1, 2026, to May 31, 2027. - Interested parties may submit capability statements, but the government has determined only Illumina, Inc. is reasonably available for this requirement. - Place of performance is the NIH Clinical Center, Department of Transfusion Medicine (DTM), Infectious Diseases Section, Bethesda, MD. - The contracting office is located at 6011 Executive Blvd., Suite 503L, Bethesda, MD 20892.

Description

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.

The National Institutes of Health (NIH) intends to award afixed price purchase order to Illumina, Inc., located at 5200 Illumina Way, San Diego, CA 92122, on a firm fixed price sole source award basis to provide the Illumina MiSeq i100 System at the National Institutes of Health, Department of Transfusion Medicine (DTM).

The instrument is manufactured and serviced by the vendor. The equipment is required by the original manufacturer (Illumina, Inc.) and it is therefore deemed to be in the Government’s best interest that this item is procured from the manufactuer.

This acquisition is being conducted using policies unique tothe Federal Acquisition Regulation (FAR) Part 13 – SimplifiedAcquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold(SAT), contracting officers may solicit from one source if thecontracting officer determines that the circumstance of thecontract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified AcquisitionProcedures are exempt from the requirements of FAR Part 6-Competition Requirements.

Interested parties may identify their interest and capabili-ties in response to this posting. The determination by the Government not to compete the proposed requirementbased upon responses to this notice is solely within the discretion of the Government.

Comments to this announcement, referencing this postingnumber, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing datespecified in this announcement, to the attention of Gregory Noland, Contract Specialist via email to gregory.noland@nih.gov by May 14, 2026 at 10 A.M. EST.

View original listing